Combination drug therapy before surgery for locally advanced gallbladder cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new approach for gallbladder cancer that has grown into nearby areas but hasn't spread far. It combines a drug called AK112 (a type of immunotherapy that helps your immune system fight cancer) with standard chemotherapy and an anti-angiogenesis drug (GAP) before surgery, in the hope of shrinking the tumor enough to allow successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of gallbladder cancer that has not spread to distant parts of the body (only local or regional).
- Your doctor and a team of experts agree that the tumor cannot be fully removed with surgery right now, but it may become removable after this treatment.
- You have not had chemotherapy, radiation, or other anti-cancer drugs for this cancer before.
- You are in reasonably good health (able to take care of yourself and up and about more than 50% of waking hours).
- Your organs (kidneys, liver, heart) are working well enough to handle the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
Hear when a new Gallbladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.